Diligence memo · auto-generated · as of July 2, 2026
Iaso Therapeutics, Inc.
Iaso Therapeutics, Inc. looks fair against its niche peers and is active on financing cadence.
Businessfiled
Iaso Therapeutics, Inc. operates in Biotechnology, based in EAST LANSING.
Sub-sector tags: pharma.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Iaso Therapeutics, Inc. has raised $1.0M in disclosed capital across 2 recorded rounds, aggregated from public filings. Its latest round is modeled as Pre-Seed (a round under $1.0M).
Largest single filing: $570K on 2026-01-09.
Most recent recorded round closed around 2026-01-09.
Valuation (modeled)modeled
Provath models Iaso Therapeutics, Inc. at approximately $1.0M (range $304K–$2.2M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Fair. Modeled value is 1.07× the median modeled value of Pre-Seed Biotechnology companies in 2025–2027 (79 peers) — value vs value, same stage and era. Within the normal band (107% of peer median) for its niche.
Financing rhythm & timingmixed
Historic cadence: a new round about every 37 months.
Last raise 6 mo ago; this sector typically re-raises about every 14 months.
Raising on or ahead of the sector's normal rhythm.
The last round stepped up 1.3× from the prior — scaling.
Comparablesmixed
Capital scale ranks ahead of 19% of Biotechnology peers (4293 compared).
Modeled value ranks above 3% of those peers.
Closest niche peers: Illexcor Holdings, LLC, Reprogram Biosciences, Inc., Maxymune Therapeutics, Inc., EnZeta Immunotherapies, Inc., Eliaz Therapeutics Inc..
Peoplefiled
6 named people on file across officers, directors and signatories.
Risks & flagsmixed
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.